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Gastroesophageal cancers (such as esophageal, gastric and gastroesophageal-junction -GEJ- lesions) are worldwide
a leading cause of death being relatively rare but highly aggressive. In the past years, a clear shift in the location of
upper gastrointestinal tract tumors has been recorded, both affecting the scientific research and the modern clinical
practice. The integration of pre- or peri-operative multimodal approaches, as radiotherapy and chemotherapy (often
combined), seems promising to further improve clinical outcome for such presentations. In the past, the definition
of GEJ led to controversies and confusion: GEJ tumors have been managed either grouped to gastric or esophageal
lesions, following slightly different surgical, radiotherapeutic and systemic approaches. Recently, the American Joint
Committee on Cancer (AJCC) changed the staging and classification system of GEJ to harmonize some staging
issues for esophageal and gastric cancer. This review discusses the most relevant historical and recent evidences of
neoadjuvant treatment involving Radiotherapy for GEJ tumors, and describes the efficacy of such treatment in the
frame of multimodal integrated therapies, from the new point of view of the recent classification of such tumors.
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Gastroesophageal cancers (such as esophageal, gastric
and gastroesophageal junction -GEJ- lesions) are world-
wide a leading cause of death, being relatively rare but
highly aggressive [1]. Gastric carcinoma was reported as
the second cause of cancer-related deaths worldwide [2],
and esophageal cancer as the sixth one [3]. In the past
years, a clear change of the more frequent locations of
upper gastrointestinal (GI) tract tumors has been re-
corded [1] both affecting the scientific research and the
modern clinical practice [4].
Frequency of the stomach’s subsite in which cancer
originates, has changed in the recent decades in Western
countries [5]. The incidence of cancer of the distal stom-
ach has decreased, while the incidence rate for cancers* Correspondence: f.cellini@unicampus.it
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stated.of the cardia and GEJ has been on a rapid upsurge [6].
Similarly, the most common site of esophageal cancer is
the distal one, which often involves the gastroesophageal
junction (GEJ) [1]. In developed countries, the incidence of
gastric cancer originating from the cardia follows that of
the esophageal cancer [7,8], suggesting similar behaviors.
Anatomically, the GEJ is the burden separating the
lower esophagus from the proximal part of the stomach,
typically in the area where the squamous epithelium of
esophagus changes into the columnar epithelium of gas-
tric cardia [9]. Adenocarcinomas of the GEJ represent
around 90% of all the GEJ cancers [10], they are gener-
ally considered to present lower radiosensitivity than
squamous cell carcinomas, but still clear evidences for
the specific subset of GEJ tumors are lacking.
Worldwide, the increased incidence of GEJ lesion is
homogeneous among western countries like USA, Canada,
Sweden, UK and most parts of Europe. The incidence of
adenocarcinomas of GEJ, cardia and esophagus increasedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Similarly, in Canada an increase of incidence of distal
esophageal and proximal gastric adenocarcinomas was
recorded from 1964 to 2002 [13]. In contrast, among
Eastern Asian countries, the non-gastroesophageal lesions
are predominant; as well, squamous cell carcinomas are
more frequent than adenocarcinomas [14].
There is a variable incidence of such disease in terms
of gender, sex, risk factors and geographical areas of in-
cidence, being Caucasian, male and over 40 years old the
most affected subgroup of patients. Predominant risk
factors include: gastroesophageal reflux disease (GERD),
Barrett’s esophagus and obesity, followed by alcohol
abuse and smoking [10,15].
Recent ameliorations of surgical techniques have
gained better results over last decades; nevertheless out-
comes after resection are still poor, ranging by 20-30%
of survival at 5 years, and optimization is needed [16].
The integration of pre- or peri-operative multimodal ap-
proaches, such as radiotherapy (RT) and chemotherapy
(CT) (also combined), is promising to further improve
clinical outcome for such presentations [17].
Purpose of this review is to discuss the most relevant
historical and recent evidences on neoadjuvant treat-
ment involving RT for GEJ tumors (in particular Phase
III trials), and to describe its efficacy among multimodal
integrated therapies, from the point of view of the new
classification.
Classification and staging of gastroesophageal junction
tumors
In past, GEJ cancers were alternatively considered as those
related with a gastric or esophageal subsite since lying at
the anatomical boundary of these two primary sites [18].
Also in clinical trials, GEJ tumors have been managed ei-
ther grouped to gastric or to esophageal lesions, following
slightly different surgical, radiotherapeutic and systemic
approaches. Therefore, the definition of GEJ in past led to
controversies and confusion [19]. Siewert and colleagues
addressed an important attempt of classification for GEJ
lesions. In the 80s, a first surgical classification based on
clinical preoperative evaluation combining diagnostic and
endoscopic features with intra-operative observations was
proposed [20,21]. In this classification, three types of GEJ
lesions were defined according to the localization of the le-
sion’s epicenter. The three types of lesion were defined onTable 1 Siewert’s classification for adenocarcinomas of GEJ
Siewert type
I
II Within 1 cm abo
III Between 2 to 5 cm below t
[GEJ: Gastroesophageal Junction].the range of distance from the GEJ (more than 1 cm
above, between 1 cm above and 2 cm below, over 2 cm
below that). In the year 2000, the ranges of distance and
the details of the definitions were slightly changed [22].
The current Siewert’s classification is summarized in
Table 1.
In 2006, the same group published the updated long-
term results of their series on over 1600 patients [23].
Particularly, they highlighted different survival trends
between the three subtypes, with better outcome for
types I/II compared to type III. Moreover, they described
the nodal spread for each type, particularly useful to
guide both surgical dissection and radiotherapy planning
(in terms of prophylactic nodal target definition).
The staging system adopted by the American Joint
Committee on Cancer (AJCC) is more oriented by patho-
logical findings. Recently, the staging system for GEJ chan-
ged, with the aim of harmonizing some staging issues
about esophageal and gastric cancer [24]. The Inter-
national Union Against Cancer (UICC) TNM Classifica-
tion reports the same changes [25]. In the 7th UICC
classification, GEJ tumors (i.e. the Siewert type I-II-III) are
grouped as a subsite of esophageal cancer, whose epicenter
is: in the distal esophagus, or in the GEJ, or as well within
the proximal 5 cm of the stomach (cardia) if extending
into the GEJ and distal esophagus. In summary, these
three types of Siewert lesions together belong to esopha-
gus according to the new classification. In particular, the
Siewert type III lesion is not considered a subsite of gastric
cancer any more (unless primary lesion originates within
the first 5 cm of stomach but not infiltrating the gastro-
esophageal junction and esophagus).
Another important change applied by the 7th classifica-
tion is related to the nodal staging definition. This is now
defined by the number of pathologically involved nodes
rather than by the location of the involved stations [24]
since this issue strongly affects prognosis. For instance, in
an experiment on 2920 patients, 5-year survival dropped
from 63% in patients without nodal involvement, to 8% in
patients with more than 6 pathologically positive nodes
[26]. This approach follows the one already in use for gas-
tric cancers [18]. According to some authors, the actual
TNM classification does not completely solve the prob-
lems for GEJ lesions and remains object of debate, still
presenting shortcomings in terms of clarity of interpret-
ation [1].Epicenter of the lesion
Within 1 to 5 cm above the anatomic GEJ
ve and 2 cm below the GEJ (i.e. true carcinoma of the cardia)
he GEJ, infiltrating GEJ and esophagus from below (subcardial carcinoma)
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the recently grouped subsites from different points of
view. The attention on the similarity of genetic mutation
profiles between distal esophagus and GEJ adenocarcin-
omas is on rise [27].
The lymphatic spread behavior is of major interest in
this regard: Leers et al. described in a recent paper the
risk of nodal involvement for adenocarcinomas from dif-
ferent primary locations [28]. Two groups, one compris-
ing 301 patients with distal esophagus lesions, and the
other comprising 208 with GEJ tumors, showed similar
rates of nodal spread (47% vs. 41% respectively); the dis-
tribution among the nodal station involved and the 5 year
survival rates, according to the authors, were also simi-
lar. On the other hand, evidences from other series sug-
gest a certain variance of aggressiveness within the GEJ
classification, among the three Siewert types. More ad-
vanced histologic grades tend to be more frequent in
types II and III than those in type I. Moreover, the per-
centage of involved nodes and the pattern of spread to
nodal stations were reported to be slightly different, with
a progressive increase of worse presentations from type I
to type III [29]. In summary, there are data not only sup-
porting the similarity of GEJ lesions to esophageal (as
grouped by TNM classification), but also about the dif-
ferences among different GEJ lesions on the basis of
Siewert’s classification. The nodal spread behavior not
only represents a parameter of oncological similarity,
and a well known risk factor strongly affecting survival
[30-32]: it is also of major importance for radiation on-
cologist, addressing the treatment volume definition and
consequently influencing efficacy and toxicity of RT. Fol-
lowing the surgical experience about anatomical spread
types and nodal involvement rates [31,33], many at-
tempts to indicate the optimal coverage of the areas at
nodal risk were made for gastroesophageal lesions
[34-36]. More recently, important studies from European
working group (as the EORTC-ROG) as the one from
Matzinger et al. [37] and single Institution experience
[38], in line with the growing clinical importance of such
an issue, have similarly deepened the GEJ lesions, sug-
gesting the optimal target contouring for each Siewert’s
type based on risk of involvement. Such considerations
support the need to consider both Siewert’s classification




Surgery is a major component of treatment for resect-
able disease. Radical surgery is the most effective treat-
ment modality, with the aim of the en-bloc removal
of primary tumor and lymphatic nodes, obtaining
microscopically negative resection margins (R0) [19].In large historical surgical series, survival was strongly
affected by the accomplishment of R0 resection: among
1602 patients, Siewert reported a 5-year survival rate of
43.2% vs. 11.1% for R0 and positive margins, respectively
(p < 0.0001) [23].
One of the major developments of surgery was the
clear reduction in surgical morbidity and mortality as a
result of improvements in staging techniques, patient se-
lection and support therapies. Nowadays, surgery alone
is mostly adopted for the treatment of early localized
presentations [1].
The efficacy of neoadjuvant integrated treatments has
been widely investigated over last the decades to overcome
the poor outcome of more advanced presentations.
A recently published meta-analysis from 17 random-
ized trials including neoadjuvant RT, chemotherapy (CT)
and surgery for esophageal carcinoma, strongly sup-
ported the adoption of combined-modality treatments
[39]. Selected trials included both neoadjuvant CT and
RT: the latter was administered as concomitant radio-
chemotherapy (RTCT) or following CT (in older stud-
ies). Results addressed a clear benefit from both RTCT
(p < 0.0001) and CT (p = 0.005) over surgery alone, and a
slightly non-significant trend favoring RTCT respect to
CT (p = 0.07). The absolute benefit was defined as an
improvement of 2-year survival of 8.7% and 5.1%with
RTCT and CT, respectively.
International Guidelines still do not completely agree on
the standard treatment approach but basically suggest
similar treatment options for adenocarcinoma of the
esophagus (that nowadays the GEJ tumors belong to). The
National Comprehensive Cancer Network (NCCN) rec-
ommends surgery alone for the very early presentations
(i.e. Tis, T1a,T1bN0), and preoperative RTCT for all the
others [1]. The National Cancer Institute (NCI) in its
Physician Data Query (PDQ) suggests preoperative RTCT
for presentation from Stage I to IV (non-metastatic) [40].
The European Society for Medical Oncology (ESMO)
indicates: surgery for early presentations; perioperative
chemotherapy for localized disease or, alternatively, pre-
operative RCTC. Preoperative RTCT and perioperative
CT are recommended for locally advanced disease [41].
Radiotherapy for gastroesphageal junction tumors:historical
evidences
Over the past 3 decades, the efficacy of RT for GEJ tu-
mors was progressively clarified.
Arnott et al. in 1998 published a meta-analysis based
on 5 available randomized trials of RT (associated to CT
or not) versus Surgery [42]. They reported a non-
statistically significant absolute survival benefit of 3% at
2 years and 4% at 5 years (HR: 0.89; CI 0.78-1.01; p =
0.062). It has to be stressed that the global accrual
period of the reported trials ranged from 1973 to 1988,
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planning and dose delivery: some of the trials even used
a Cobalt treatment unit. Moreover, the RT dose ranged
from 20 to 40 Gy among the studies (lower than the
most commonly used nowadays). The main characteris-
tics of this and other meta-analyses mentioned in this
review are summarized in Table 2.
Walsh et al. in 1996 published a landmark random-
ized study on esophageal tumors addressing the role of
RT for GEJ adenocarcinomas. Cardiac tumors (at least
considerable as Siewert II-III), or middle and lower third
esophageal cancers (the latter is considerable at least in
part as a Siewert I: details were not reported in detail by
authors) [43]. This trial was not included in the Arnott’s
meta-analysis [42]. Between 1990 and 1995, 113 patients
affected by adenocarcinoma were enrolled and random-
ized to either RTCT followed by surgery or surgery
alone. The rate of patients affected by lesions of the mid-
dle third of the esophagus was 14.1%, the remaining
85.9% are at least considerable GEJ in the modern classi-
fication. Patients in the experimental arm received
RTCT (with 5-Fu and CDDP) up to a dose of 40 Gy
(with 2.7 Gy per fraction in 15 fractions over 3 weeks).
Of the 52 patients who underwent surgery in the RTCT
arm, 13 (25%) presented pathological complete response
(pCR). Median survival was 16 and 11 months (mth) for
preoperative RTCT and surgery-only arm (p = 0.01), re-
spectively. The 1-, 2- and 3-year survival rates were 52%,
37%, and 32% in the RTCT arm, and 44%, 26% and 6%
in the surgery-only one, respectively (p = 0.01).
Between 1998 and 1999, two randomized trials testing
the superiority of RTCT over RT alone in the preopera-
tive setting of esophageal tumors were published [44,45].
These studies are not really representative of GEJ adeno-
carcinomas due to their eligibility criteria. Smith et al.
enrolled approximately 50% of the patients with the pri-
mary site of tumor in the lower third of esophagus, but
all patients presented SCC lesion; Cooper et al. enrolled
all patients with primary site in the thoracic esophagus.
Anyway, these trials encouraged the approach of follow-
ing experiences for esophageal cancer, towards RTCT in
the preoperative setting [17].
In 2001, Urba et al. published a randomized trial on
preoperative RTCT versus surgery only [46] on patients
presenting tumor of the esophagus or GEJ. It is difficult to
precisely define the rate of GEJ tumor in patients enrolled
in this trial, according to the modern definition. Ninety-
two percent of patients in both arms had a middle or
lower third lesion, with a rate of upper third lesions lower
than 10%. Adenocarcinoma accounted for 75% (only 24%
of squamous cell carcinoma). One hundred patients were
enrolled from 1989 to 1994: 50 patients received RTCT
with a total dose of 45 Gy (1.5 Gy per fraction, two frac-
tion per day, over 21 days), concurrently with 5-FU, CDDPand vinblastine. In the surgery-only arm 90% (45/50) had
a gross total resection; and in the RTCT arm 95.7% (45/47
who underwent surgery) had a gross total resection. In the
experimental arm, 28% had a pCR (14/50, according to
intention to treat). Median survival and 3-year survival for
surgery and RTCT arms were 17.6 vs. 16.9 mth, and 16%
vs. 30% (p = 0.15), respectively. It has to be noted that this
study was statistically powered to detect a relatively large
increase in median survival, and that the dose fraction-
ation and CT association differed from the more common
standards. Interestingly, when considering the survival
by pathological response, a clear significant benefit was
found: the reported median survival and 3-year survival
rate for the pCR group versus the non-pCR were 49.7 vs.
12 mth, and 64% vs. 19%, respectively, highlighting the im-
portance of preoperative effective treatment for responder
patients.
Fiorica et al. in 2004 published a meta-analysis in-
cluding 6 trials of RTCT versus surgery alone [47]. This
study included the two papers by Walsh et al. and Urba
et al. mentioned above.
Authors not only showed a significant survival benefit of
neoadjuvant RTCT over surgery alone (HR: 0.53; CI: 0.31-
0.92; p = 0.03), but also highlighted a significant risk for
postoperative mortality. Two considerations should be ad-
dressed. First, the reported survival benefit was still not
strong in itself. Survival evidence of benefit was lost for
the exclusion from the statistical evaluation of either the
study from Walsh, or the one from Urba. Therefore, the
need for further evidence was clear. Second, the toxicity
related to neoadjuvant RTCT was mainly due to the con-
tribution of a trial by Bosset et al., using non-conventional
RT doses and fractionations, also questioned by its
Authors, and no longer used in the following experiences
[17] (see also Table 2).
Recent randomized trials of radio(chemo)therapy plus
surgery versus surgery alone
Burmeister et al. in 2005 [48] failed to report a signifi-
cant benefit adding preoperative RTCT to surgery alone.
Between 1994 and 2000, they randomized 256 patients.
Lesions were cited in the proximal or middle esophagus
for 23% in the RTCT arm and for 19% in the surgery
alone one. Distal esophageal lesions (more representative
for GEJ) accounted for 77% in the RTCT arm and for
81% in the surgery alone one. Primary lesions originating
in cardia with predominant esophageal invasion (similar
to Siewert III) were included. Adenocarcinomas were ap-
proximately 60% in both arms. RTCT delivered 35 Gy
(in 15 fraction of 2.4 Gy over 3 weeks) with concurrent
5-FU and CDDP. RTCT was well tolerated: esophagitis
was the highest Grade 3-4 toxicity, reported in 16% of
patients. There was no significant benefit for progression
free and overall survival in the RTCT arm respect to the
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was reported. It is interesting to highlight that in the ex-
perimental arm, a significantly higher R0 resection rate
(80% vs. 59%; p = 0.0002), and lower rate of pathologic-
ally positive lymph-nodes (43% vs. 67%; p = 0.003) were
reported. Patients in the RTCT arm reported 16% rate of
pCR. It should be highlighted that the RT dose was
lower than that in the other modern randomized trials
that reported an outcome improvement.
In 2008, Tepper et al. published a trial on patients
with esophageal or GEJ tumor (both squamous and
adenocarcinomas) [49]. Lesions of the thoracic esopha-
gus (below 20 cm), and/or GEJ with less than 2 cm distal
spread into the cardia (the latter corresponds to the ac-
tual Siewert II) were included. The rate of lesions in the
thoracic esophagus was not specified, but 75% of the 56
enrolled patients had adenocarcinoma (orienting for a
major presence of GEJ lesions). Between 1997 and 2000,
30 patients in the experimental arm received RTCT with
a total dose of 50.4 Gy (45 Gy in extended field + 5.4 Gy
as boost; conventional fractions over 5.5 weeks) plus
concomitant 5-FU and CDDP. Grade 3-4 esophagitis
was the highest non-hematological toxicity, reported in
26% for RTCT. Pathological data were available only for
25/30 patients in the RTCT arm: pCR was reported for
40% (10/25). At a median follow-up (fup) of 6 years, ac-
cording to intent-to-treat analysis there was a significant
survival benefit for RTCT over surgery alone. Median
survival was 4.48 vs. 1.79 years and 5-year survival was
39% vs. 16% for RTCT and surgery alone, respectively
(p = 0.002). The study was prematurely closed due to
poor accrual (respect to the 475 planned), and suffered
for this statistical bias.
Van Hagen et al. in 2012 published the “Chemoradio-
therapy for esophageal cancer followed by surgery study”
(CROSS) trial, advocated as potential gold standard for
esophageal cancer [50]. Between 2004 and 2008, 366 pa-
tients affected with esophageal or GEJ carcinoma were
enrolled. Pure GEJ lesions were reported in around 25%
of patients. Over 80% of the patients in both the arms
had primary lesion cited in the distal third lesion or
at the GEJ, and adenocarcinomas accounted for 75%.
RTCT consisted of a dose of 41.2 Gy (conventional frac-
tionation, over 5 weeks) plus weekly Carboplatin and
Paclitaxel. Tolerance to RTCT was good: 91% of patients
in experimental arm received the full treatment regimen.
In the RTCT group, 94% of patients underwent surgery
versus 99% in the control arm (p = 0.01); seven patients
in RTCT group showed disease progression during treat-
ment, compared to one in the surgery-only group. An
R0 resection was obtained for 148/161 patients (92%)
versus 111/161 (69%) in the RTCT and control group re-
spectively (p < 0.001). At a median fup of 45.4 mth, the
3- and 5-years overall survival rates were 58% vs. 44%and 47% vs. 24% for combined treatment and surgery
alone arms, respectively (p = 0.003).
Two of the most interesting pathological findings
should be highlighted. The first is the 29% rate of pCR
(47/161) in the RTCT group, higher but in line with the
previously published evidences for GEJ tumors. Second:
the significantly lower presence of pathological nodal in-
volvement in the RTCT compared to the surgery only
arm: 31% vs. 75% respectively (p < 0.001).
In 2014, a specific analysis of the relation between the
site of recurrence and radiation field in CROSS I and II
trials was published [51]. Oppedijk et al. showed that RT
significantly improved over surgery alone both locoregio-
nal recurrence (14% vs. 34%; p < 0.001) and peritoneal car-
cinomatosis (4% vs. 14%; p < 0.001), also presenting a
small but significant benefit on hematogenous dissemin-
ation rates (29% vs. 35%; p = 0.025). Recurrences within
the RT treatment volume occurred in only 5% (11/213)
evaluable patients.
The main randomized trials of RTCT plus Surgery ver-
sus Surgery alone are summarized in Table 3.
Randomized trials of radio(chemo)therapy versus
chemotherapy
Two randomized trials recently compared RTCT versus
CT in the preoperative setting.
Burmeister et al. randomized in a phase II trial, be-
tween 2000 and 2006, 75 patients presenting resectable
adenocarcinoma of the esophagus and GEJ. The planned
accrual was 100 patients, but was reduced due to poor
accrual in the RTCT arm for technical reasons. Treat-
ment consisted of either CT with 5-FU and CDDP, or
RTCT delivering a dose of 35 Gy (in 15 fractions of
2.4 Gy over 3 weeks) concomitantly to the same drugs at
reduced doses [52]. Similarly to their previous trial com-
paring RTCT to surgery alone [48], RT dose was lower
than in other reported trials: again RTCT failed to sig-
nificantly improve outcomes. Nevertheless, in the RTCT
group a positive trend was reported for progression free
survival (14mth-CT vs. 26 mth-RTCT; p = 0.37) and
overall survival (29mth-CT vs. 32mth-RTCT; p = 0.83).
It is interesting that the RTCT approach gained signifi-
cantly higher pathological response rates (RTCT 31%
versus CT 8%; p = 0.01) and R1 resection rates (RTCT
0% versus CT 11%; p = 0.04). Toxicity profiles were simi-
lar in the 2 arms. The statistical power of this study
should be interpreted with caution, especially in regard
to progression free survival. Authors concluded that the
most important evidence was about the not increased
toxicity and the superior pathological response in the
combined arm.
Stahl et al. published in 2009 a phase III trial on 126
patients (enrolled between 2000-2005) affected by adeno-
carcinoma of the lower esophagus and cardia (Siewert
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(with CDDP, 5-Fu, Leucovorin) or 12 weeks of the same
CT followed by 3 weeks of RTCT (30 Gy with conven-
tional fractionation plus CDDP and Etoposide). In the
RTCT arm, a significant improvement of the pCR rate
(RTCT: 15.6% vs. CT: 2.0%; p = 0.03) was reported. Also
the tumor-free lymph-nodes rate was significantly higher
in the RTCT group (RTCT: 64.4% vs. CT: 36.7%; p = 0.01).
Preoperative RT showed a positive non-significant trend in
the 3-year survival rates (RTCT: 27.7% vs. CT: 47.4%; p =
0.07). It is important to stress as the non significance of
such results should be carefully interpreted for some rea-
sons: the study was statistically designed to detect a 10%
improvement in the 3 year survival for the RTCT arm,
expecting a much larger accrual in each arm; almost a
20% of improvement was actually reported, but the total
number of needed patients after the planned first stage of
the protocol required 163 additional patients per arm,
then the study was closed without obtaining the required
statistical power. Moreover, the impact of the pathological
findings reflected the subgroup survival analysis: the
pathologically node-negative patients had a significantly
higher 3-year survival (64.2% vs. 38.8%; p < 0.001). Patients
achieving pCR were all alive at the median follow-up time
of 4.1 years, independently by administered treatment.
About the tolerance of preoperative RTCT, a non-
significantly increased postoperative mortality in the
RTCT arm (10.2% vs. 3.8%; p = 0.26) was reported: this
data is not completely in line with the others experiences
in literature (in particular the available meta-analyses sug-
gest a risk of postoperative morbidity slightly decreasing
in the more recent trials), and the 12 weeks of CT induc-
tion before RTCT could have played a role.
A final consideration on the study by Stahl should be
addressed about the absolute pCR rate reported in the
RTCT arm. Even though the pCR rate in RTCT is sig-
nificantly higher than that in the CT arm, it is consider-
ably lower than that in the previously mentioned series.
It is arguable (as suggested by the authors) that the low
RT dose had an influence on that aspect. It could also
be hypothesized that the choice of the RT dose was in-
fluenced by attempt to keep the overall duration of the
RTCT treatment similar to the CT one (i.e. 15 weeks).
We have already highlighted, among the previously
cited clinical experiences, that inducing a pCR after neo-
adjuvant treatment is crucial for the prognosis. This is a
known issue, highlighted from historical series of specific
experiences on both esophageal and gastric tumors
[54-56]. That issue was also recently confirmed in one of
the largest single center retrospective series, published
by Fields et al. [57]. They reviewed cases from 714 pa-
tients treated between 1985 and 2009 at the Memorial
Sloan-Kettering Cancer Center: all of them were treated
with preoperative therapy (i.e. CT with or without RT)for localized gastric or GEJ adenocacinoma. On 714
treated patients, 609 had an R0 resection after pre-
operative treatment. The vast majority of R0 patients
had GEJ lesion (359/609 -60% of pure GEJ only; 439/
609-72% of pure GEJ + proximal gastric lesions). A
whole rate of 8.4% (60/609) of pCR was reported. These
patients showed significantly lower rate of 5-year recur-
rence compared to non-pCR patients (27% versus 51%;
p = 0.01). It is arguable that the low absolute rate of
pCR is due to the long time frame of evaluation, mean-
ing older RT treatments and drugs administered.
Ronellenfitsch et al. published in 2013 a meta-analysis
based on aggregate and individual patient data collecting
randomized phase III trials comparing surgery alone ver-
sus surgery preceded by neoadjuvant treatment at least in-
cluding CT (either alone or combined with RT). It
summarizes some issues debated in this review. Authors
collected 14 phase III trials on adenocarcinoma, of esopha-
gus, GEJ or stomach: time to death from randomization,
on an intention-to-treat base was the primary outcome
[16]. They highlighted that administration of CT (globally
evaluated as preoperative CT alone + RTCT) gained sig-
nificantly longer survival respect to surgery alone, with an
absolute benefit of 9% at 5-year survival (HR 0.81, CI 0.73-
0.89; p < 0.0001). Moreover, a longer disease free survival,
higher down staging rate and R0 resection probability were
reported. Preoperative therapy was not associated to
higher postoperative complication likelihood. When separ-
ately analyzed by anatomical subsites, the reported results
were largest for the GEJ presentations, followed by esopha-
geal and gastric tumors. In direct subgroup analysis, RTCT
showed a larger (but not significant) effect then CT in pro-
ducing the survival benefit (HR: 0.70, CI 0.50-0.99 for
RTCT vs. 0.83, CI 0.75-0.91 for CT; p = 0.38). Authors
summarize that the available evidences suggest a benefit
from adding RT to CT for adenocarcinoma of GEJ and
esophagus.
It is also relevant to note that due to the timing of the
meta-analysis, the CROSS trial from Van Hagen [50]
was not included, and it is arguable that it could have
enhanced the statistical power.
Sign of the interest and relevance of the issue of pre-
operative RTCT for adenocarcinoma of the pure GEJ is
provided by the growing number of new clinical experi-
ences focused on it, involving the new RT technologies,
and providing positive results: Platz et al. reported in 2013
as intensity-modulated-RT (IMRT) up to 50 Gy plus CT,
produced 100% of R0 resection rate and 38% of pCR in a
group of 16 patients [58]. At a median follow-up of 15.3
mth (9.8-20), 3/16 patients had recurrence (1 anastomotic,
2 distant nodal). Moreover, some important PhaseII/III
studies focused on preoperative RTCT on GEJ tumors are
currently registered and on-going, as the TOPGEAR trial
from the collaboration of EORTC -TROG (Identifier:
Cellini et al. Radiation Oncology 2014, 9:45 Page 9 of 11
http://www.ro-journal.com/content/9/1/45NCT01924819), randomly evaluating perioperative CT as-
sociated or not to preoperative RTCT. At least 2 other
studies are focused on preoperative RTCT in the specific
population of GEJ lesion only lesions: one from a Chinese
group in Hebei (Identifier: NCT01962246) evaluating
RTCT versus CT alone for Siewert types II-III; the other
from a Polish one in Lublin (Identifier: NCT01523015)
comparing RTCT (for type I-II) or CT alone (for type III)
plus surgery versus surgery alone. In line with the growing
trend of research on the new molecular targeted agents
for GEJ tumors, studies are on-going specifically recruiting
patients with GEJ lesions. Many biologically targeted
agents are under evaluation, but again the research sce-
nario is still often recruiting GEJ tumors together with
esophageal and gastric ones. Evidences seem more than
promising, particularly oriented to drugs targeting EGFR,
VEGF and HER, this last one seems one of the most
promising agents based on the still few evidences from
direct evaluation of these drugs in concomitant combin-
ation with RT [4]. Still more robust evidences are needed
to clearly define the optimal strategy, moreover we must
be aware of the difficulties in defining response profiles:
attempts in this direction are addressed to individuate
genetic signatures profiling the GEJ tumors [59,60], their
response to therapies [61] or specific genes and molecules
potential candidates for new drug development [62]. Fi-
nally, also the presence of specific histological patterns as
signet ring cells or mucinous histology could be predictive
of worse prognosis and better response to RTCT [63,64]
and should be included in the treatment decision process
or new trial setting, but evidences in this regard are still
not conclusive [65].
Conclusions
Looking at the main evidences reported in literature
about the role of RT in the multimodal management of
GEJ adenocarcinomas, some problems are still evident
in term of clarity of the classification, patient selections
in the trial and evaluation of results. Nevertheless, we
can summarize that the integration of preoperative RT
before surgery is highly effective over surgery alone, pro-
viding significantly improved results in terms of local
control and survival, with acceptable toxicity rates. In
this setting, RT should be administered at least to a total
dose of 40-45 Gy (with conventional fractionation), and
associated to concomitant chemosensibilization. A non-
significant positive trend gaining better results over pre-
operative CT alone is also reported in literature. To de-
fine the best treatment option, a new randomized trial,
with a particular attention to accrual criteria, taking into
account both TNM and Siewert’s classification is needed.
To tailor the future treatment approaches, it is crucial to
consider the molecular profile of the disease and include
the more promising new molecular targeted therapies,as well as considering the new option of RT delivering
coming from new technologies.
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